Furthermore, clinical data advocate for the co-administration of histamine with IL-2 and/or IFN-α to prolong survival time and to suppress tumors, such as MM and liver melanoma, which are refractory to IL-2 or IFN-α therapy [66]. This evidence concerns the gene IL2 and Miyoshi myopathy.